Group 1 - The core viewpoint of the news highlights significant achievements in the innovation drug sector, with a record 76 innovative drugs expected to be approved for market in China by 2025, marking a historical high [1] - The healthcare payment system is continuously optimized, with the introduction of a "commercial insurance innovative drug directory" mechanism, which enhances the payment capacity for innovative drugs through the complementary combination of medical insurance and commercial insurance [1] - Institutions are optimistic about the pharmaceutical and biotechnology industry, with Donghai Securities predicting that China will officially enter a new era of innovative drugs by 2026 [1] Group 2 - The Hong Kong Stock Connect Innovative Drug ETF managed by Harvest (520970) tracks the CSI Hong Kong Stock Connect Innovative Drug Index, with the top ten weighted stocks including WuXi Biologics, Innovent Biologics, BeiGene, and others, accounting for over 71.80% of the total weight [2] - The management and custody fees for the Harvest Hong Kong Stock Connect Innovative Drug ETF are 0.60% per year, making it suitable for both ordinary investors as a long-term allocation tool and professional investors for flexible trading needs [2]
创新药获批数量创新高，医保商保双轮驱动，港股通创新药 ETF 嘉实（520970）持续受关注
Jin Rong Jie·2026-01-08 02:23